Live Breaking News & Updates on Navitoclax

Stay informed with the latest breaking news from Navitoclax on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Navitoclax and stay connected to the pulse of your community

Adding Navitoclax to Ruxolitinib Doubles Spleen Volume Reductions for Myelofibrosis

Up-front treatment with navitoclax plus ruxolitinib significantly reduced spleen volume by 35% or more at week 24 vs ruxolitinib plus placebo in patients with myelofibrosis; however, a significant difference was not observed in total symptom score v. 4.0 between the arms, according to data from the phase 3 TRANSFORM-1 study.

Texas , United-states , Houston , Naveen-pemmaraju , Department-of-leukemia , University-of-texas-md-anderson-cancer-center , Cancer-center , Navitoclax , Navitoclax-plus-ruxolotinib , Myelofibrosis , Ash , Ash-annual-meeting

Addition of Navitoclax to Dabrafenib/Trametinib Aims to Improve Efficacy of Targeted Therapy in BRAF+ Metastatic Melanoma

Zeynep Eroglu, MD, explains the rationale for adding navitoclax to dabrafenib plus trametinib in the treatment of patients with BRAF V600–mutant metastatic melanoma, highlights the methodologies and results of the CTEP-P9466 trial, and describes the implications of this research for this patient population.

Tampa , Florida , United-states , Massachusetts , Zeynep-eroglu , Ryan-sullivan , Department-of-oncologic-sciences , Cutaneous-oncology , Moffitt-cancer-center , Oncologic-sciences , South-florida-morsani-college , Massachusetts-general-hospital

Dabrafenib and Trametinib Plus Navitoclax Meets CR End Point in BRAF V600–mutant Metastatic Melanoma

The combination of dabrafenib and trametinib plus navitoclax generated responses and met the co-primary end point for complete response rate vs historical controls in patients with BRAF V600–mutant metastatic melanoma.

Florida , United-states , Tampa , Anita-giobbie-hurder , Zeynep-eroglu , Genentech-roche , Elsevier , Novartis , Boehringer-ingelheim , Pfizer , Department-of-oncologic-sciences , Cutaneous-oncology

Potential Combination Therapy Approaches with Ruxolitinib in Myelofibrosis

A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.

Myeloproliferative-neoplasms , Combination-therapy-approaches , Myelofibrosis , Novel-combination-therapy , Ruxolitinib , Jak2-inhibitor , Pelabresib , Pegylated-interferon-alpha , Navitoclax , Bcl-xl , Bcl-2